Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026

Impact · against what's priced in

Oruka Therapeutics is set to report Phase 2b data for ORKA-001, creating a binary catalyst event for the stock. While the announcement of the data release is a scheduled milestone, the actual results will determine if the pipeline's NPV is re-rated.

Scored by the NIS engine · methodology.

Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026

phase 2New
clinical trials

Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026

What matters in this story

How each ticker is affected

Odyssey Therapeutics Highlights OD-001 Phase IIa UC Data, Sets 2027 Trial Readouts

Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026

What matters in this story

How each ticker is affected

Odyssey Therapeutics Highlights OD-001 Phase IIa UC Data, Sets 2027 Trial Readouts

Track these names every morning.

Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer

Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026

Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)

Ocular Therapeutix: The Drug Won, The Stock Lost, And That's The Opportunity

Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026

What matters in this story

How each ticker is affected

Next reads from the same story arc

Odyssey Therapeutics Highlights OD-001 Phase IIa UC Data, Sets 2027 Trial Readouts

Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026

What matters in this story

How each ticker is affected

Next reads from the same story arc

Odyssey Therapeutics Highlights OD-001 Phase IIa UC Data, Sets 2027 Trial Readouts

Track these names every morning.

Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer

Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026

Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)

Ocular Therapeutix: The Drug Won, The Stock Lost, And That's The Opportunity